Tanomastat

• Description:

  Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models[1][2][3].

• Product Name Alternative:

  BAY 12-9566

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H312, H332

• Target:

  MMP

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tanomastat.html

• Purity:

  99.7

• Solubility:

  DMSO : 25 mg/mL (ultrasonic; warming)

• Smiles:

  ClC1=CC=C(C2=CC=C(C(C[C@H](CSC3=CC=CC=C3)C(O)=O)=O)C=C2)C=C1

• Molecular Formula:

  C23H19ClO3S

• Molecular Weight:

  410.91

• Precautions:

  H302, H312, H332

• References & Citations:

  [1]Leung D, et al. Protease inhibitors: current status and future prospects. J Med Chem. 2000 Feb 10;43 (3) :305-41.|[2]Gatto C, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res. 1999 Nov;5 (11) :3603-7.|[3]Nozaki S, et al. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancerorthotopic model. Clin Exp Metastasis. 2003;20 (5) :407-12.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• Isoform:

  MMP-13; MMP-2; MMP-3; MMP-9

• CAS Number:

  179545-77-8